Claims for Patent: 9,067,992
✉ Email this page to a colleague
Summary for Patent: 9,067,992
| Title: | Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis |
| Abstract: | The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis. |
| Inventor(s): | Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL) |
| Assignee: | AbbVie Biotechnology Ltd. (Hamilton, BM) |
| Application Number: | 14/563,056 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,067,992 |
| Patent Claims: | 1. A method of treatment of moderate to severe active psoriatic arthritis in adult patients, wherein each said patient has .gtoreq.3 swollen and .gtoreq.3 tender joints prior
to the treatment and has failed NSAID therapy, comprising subcutaneously administering to each said patient 40 mg of adalimumab every other week, wherein 23% of said patients achieve 70% reduction in American College of Rheumatology (ACR) score at week
24 of the treatment.
2. A method for reducing or inhibiting symptoms in a patient with psoriatic arthritis, comprising subcutaneously administering to said patient 40 mg of adalimumab every other week. 3. The method of claim 2, wherein said 40 mg adalimumab is comprised in a pre-filled syringe for subcutaneous injection. 4. The method of claim 3, wherein said 40 mg adalimumab is formulated at a concentration of 50 mg/ml. 5. The method of claim 2, wherein the patient achieves at least a 50% reduction in ACR score at week 24 of the treatment. 6. The method of claim 5, wherein the patient achieves at least a 70% reduction in ACR score at week 24 of the treatment. 7. The method of claim 2, wherein said symptoms are progression of structural damage assessed by radiograph. 8. The method of claim 7, wherein said 40 mg adalimumab is comprised in a pre-filled syringe for subcutaneous injection. 9. The method of claim 8, wherein said 40 mg adalimumab is formulated at a concentration of 50 mg/ml. |
Details for Patent 9,067,992
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | December 31, 2002 | 9,067,992 | 2021-03-07 |
| Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | February 21, 2008 | 9,067,992 | 2021-03-07 |
| Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | April 24, 2013 | 9,067,992 | 2021-03-07 |
| Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | September 23, 2014 | 9,067,992 | 2021-03-07 |
| Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | November 23, 2015 | 9,067,992 | 2021-03-07 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Showing 1 to 5 of 5 entries
International Patent Family for US Patent 9,067,992
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 040603 | ⤷ Try for Free |
| Argentina | 045710 | ⤷ Try for Free |
| Argentina | 077474 | ⤷ Try for Free |
| Argentina | 077573 | ⤷ Try for Free |
| Argentina | 098173 | ⤷ Try for Free |
| >Country | >Patent Number | >Estimated Expiration |
Showing 1 to 5 of 5 entries
